Article

Suresh Ramalingam on Toxicities Associated With Immunotherapy in Different Disease Types

Author(s):

Suresh S. Ramalingam

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Related Videos
Image of man with grey hair.
Image of woman with black hair.
Image of a smiling woman with brown hair.
Image of a woman with short brown hair, wearing glasses.
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a black button-up shirt.
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Related Content
Image of a smiling woman with brown hair.
December 20th 2024

How to Self Advocate When Insurance Says No to Cancer Treatment Coverage

Ashley Chan
When insurance denies coverage of cancer treatment, patients with cancer don’t need to take no for an answer, an expert explained.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
"FDA" text.
December 13th 2024

FDA Approves Unloxcyt for Locally Advanced, Metastatic Skin Cancer Subset

Ashley Chan
Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell carcinoma.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of a heart monitor.
December 9th 2024

Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers

Ashley Chan
In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.
‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself
December 5th 2024

‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself

Alex Biese
Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.